Fig. 3

CTGF is a direct target of miR-375. a. Correlation between CTGF expression level and glioma grade. CTGF expression levels in glioma in TCGA RNA-seq (left), CGGA RNA-seq (right) databases. b. Prognosis efficiency of CTGF in WHO grade patients within the CGGA RNA-seq data. c. Predicted binding sequence of human hsa-miR-375 and its binding site in the 3′-UTR of CTGF presented for alignment. d. StarBase v2.0 analysis demonstrating a negative correlation between miR-375 and CTGF in low-grade glioma (LGG). e. Expression of candidate target gene CTGF in U87 and U251 cells as assessed by qRT-PCR following overexpression of miR-375. f. Western blot analysis of CTGF in U87 (left) and U251 (right) cells following miR-375 treatment. GAPDH was used as an internal control. g. CTGF levels measured by ELISA following miR-375 treatment. All experiments repeated independently three times. Data are presented as mean ± standard deviation. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significant